Pharmaceutical Preparations · L3 · CIK 818686
Teva Pharmaceutical Industries Ltd. manufactures and markets generic and specialty pharmaceuticals
Comparable business profile · signals at a glance
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Sabag Mark"See ""Remarks""" | Sell | 62,102 | $30.14 | $1.9M |
| Mar 5, 2026 | Francis Richard DPresident and CEO | Sell | 20,025 | $31.67 | $634K |
| Mar 5, 2026 | Shields MatthewEVP, Global Operations | Sell | 17,295 | $31.67 | $548K |
| Mar 5, 2026 | Daniell RichardEVP, Europe Commercial | Sell | 17,295 | $31.67 | $548K |
| Mar 5, 2026 | Jover Placid"See ""Remarks""" | Sell | 14,150 | $31.67 | $448K |
| Mar 5, 2026 | Hughes Eric A"See ""Remarks""" | Sell | 9,533 | $31.67 | $302K |
| Mar 5, 2026 | Fox ChristineEVP, U.S. Commercial | Sell | 7,924 | $31.67 | $251K |
| Mar 5, 2026 | Savage BrianInterim Chief Legal Officer | Sell | 1,127 | $31.67 | $36K |
| Mar 4, 2026 | Daniell RichardEVP, Europe Commercial | Sell | 37,372 | $32.95 | $1.2M |
| Mar 4, 2026 | Daniell RichardEVP, Europe Commercial | Sell | 33,512 | $32.46 | $1.1M |
| Mar 4, 2026 | Francis Richard DPresident and CEO | Sell | 23,393 | $32.46 | $759K |
| Mar 4, 2026 | Daniell RichardEVP, Europe Commercial | Sell | 20,461 | $32.46 | $664K |
| Mar 4, 2026 | Hughes Eric A"See ""Remarks""" | Sell | 11,277 | $32.46 | $366K |
| Mar 4, 2026 | Fox ChristineEVP, U.S. Commercial | Sell | 9,098 | $32.46 | $295K |
| Mar 4, 2026 | Savage BrianInterim Chief Legal Officer | Sell | 1,489 | $32.46 | $48K |
| Mar 4, 2026 | Savage BrianInterim Chief Legal Officer | Sell | 1,186 | $32.46 | $38K |
| Mar 3, 2026 | Francis Richard DPresident and CEO | Sell | 412,032 | $32.36 | $13.3M |
| Mar 3, 2026 | Hughes Eric A"See ""Remarks""" | Sell | 68,685 | $32.36 | $2.2M |
| Mar 3, 2026 | Daniell RichardEVP, Europe Commercial | Sell | 66,735 | $32.36 | $2.2M |
| Mar 3, 2026 | Daniell RichardEVP, Europe Commercial | Sell | 62,250 | $32.36 | $2.0M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.